Document resource
Background In MycarinG ( NCT03971422; Phase 3), adults with generalised myasthenia gravis (gMG) received one 6-week rozanolixizumab treatment cycle. All patients who enrolled in MG0007 (NCT04650854; open-label extension) received one further treatment cycle with subsequent need-based cycles initiated at the investigator’s discretion. Thus, cycle number and treatment-free intervals varied per patient.Methods Clustering analysis was conducted on the number of cycles per year (CPY) in patients with ≥1 cycle from MycarinG and MG0007 (data cut-off: 08 July 2022). Baseline characteristics were assessed for association with CPY using multivariate regression models. Treatment-emergent adverse events were compared among clusters.Results Balanced clustering and optimal goodness-of-fit was achieved using three clusters to describe CPY (low: <2.59; medium: 2.59–4.64; high: >4.64). Mean (standard deviation) CPY in each cluster was 1.50 (0.53, n=74), 3.59 (0.60, n=64) and 5.82 (0.72, n=50), respectively. Overall, baseline characteristics were balanced between clusters and were not predictive of CPY for patients. Rozanolixizumab was generally well tolerated across the clusters.Conclusions These three treatment clusters demonstrate that rozanolixizumab cycle cadence varies between patients, from 1–7 CPY. This suggests an individualised approach to rozanolixizumab treatment based on each patient’s own gMG experience, as the study included a broad, adult gMG population.rowan.orme@ucb.com